[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Min Su\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":117},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,36,65,93],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":28,"completionDateStruct":30,"leadSponsor":32,"locationsCount":35},"100615566","construction-and-clinical-validation-study-of-a-prediction-model-for-depression-after-ischemic-stroke-100615566",false,"NCT07294274","Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke","Inclusion Criteria:\n\n* Patients with acute ischemic stroke;\n* Admission within 7 days of symptom onset;\n* The patient and\u002For the family members sign a written informed consent form.\n\nExclusion Criteria:\n\n* Confusion of consciousness,severe cognitive impairment, etc\n* Individuals with a history of depression, schizophrenia, bipolar disorder, etc;\n* Individuals unable to participate in neuropsychological examinations due to hearing im pairments, lack of coordination, or neurological deficits, including se vere aphasia.","ALL",{"count":17,"type":18},488,"ESTIMATED","OBSERVATIONAL","Post-stroke depression (PSD) is the most common neuropsychiatric disorder after a stroke, with an incidence rate of 20% to 60%. PSD is not only associated with higher mortality rates, poorer recovery, more obvious cognitive impairments, greater economic burdens, and lower quality of life, but also brings additional medical expenses and care pressure to families. Society also needs to bear higher medical costs. Currently, the early diagnosis of PSD is difficult, which may lead to poor prognosis after stroke. This study aims to utilize machine learning technology to integrate multi-dimensional indicators of patients with ischemic stroke, establish a risk prediction model for PSD, and assist in early, accurate, and individualized assessment of PSD risk in clinical practice.",[22],"Post-stroke Depression","RECRUITING","2026-02-03",{"date":26,"type":27},"2026-02-05","ACTUAL",{"date":29,"type":27},"2025-11-01",{"date":31,"type":18},"2026-07-20",{"name":33,"class":34},"Min Su","OTHER",1,{"id":37,"slug":38,"hasResults":11,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":4,"eligibilityCriteria":42,"healthyVolunteers":11,"sex":15,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},"100612006","early-phase-1-subanesthetic-esketamine-in-modified-ect-for-severe-depression-in-adolescents-clinical-and-mechanistic-study-100612006","NCT07247968","Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study","Clinical and Mechanistic Study of Subanesthetic-dose Esketamine in Modified Electroconvulsive Therapy for Adolescents With Severe Depression","Inclusion Criteria:\n\n* Inpatients diagnosed with Major Depressive Disorder according to the International Classification of Diseases,11th Revision(ICD-11),and scheduled for Modified Electroconvulsive Therapy(MECT);\n* Aged 13 to 17 years,regardless of gender;\n* Educational attainment of primary school or higher;\n* Normal hearing and vision,including color perception;\n* Voluntary participation in the study with signed informed consent;\n* American Society of Anesthesiologists(ASA)physical status classification I-II.\n\nExclusion Criteria:\n\n* Severe cardiovascular disease,significant arrhythmias,or other cardiac conditions;\n* Inability to complete the assessment scales;\n* History of substance abuse;\n* Received electroconvulsive therapy(ECT)within 6 months prior to the study;\n* Severe cerebrovascular disease,severe hypertension,intracranial hypertension,or presence of intracranial electrodes;\n* Severe allergy or contraindication to propofol or succinylcholine;\n* Comorbid with other psychiatric disorders.","13 Years","17 Years",{"count":46,"type":18},220,"INTERVENTIONAL",[49],"EARLY_PHASE1","The study design was a randomized, double blind, parallel controlled trial.The goal of this clinical trial is to learn if esketamine-assisted modified electroconvulsive therapy (ESK-MECT) works to treat severe depression in adolescents. It will also learn about the safety of ESK-MECT.\n\nThe sample size was calculated based on the response rate of patients with depression undergoing electroconvulsive therapy(ECT).According to the results of the pilot study,the efficacy rate of subjects receiving adjunctive esketamine was approximately 78%,while the efficacy rate of those receiving only propofol was 63%.The expected superiority difference in remission rates between the two groups was 15%(one-sided)for the power calculation.Assuming a significance level of α=0.05 and a test power of β=0.2,with a 1:1 ratio of sample sizes between the two groups,the total sample size was calculated to be 198 using the PASS software(PASS 2023).Considering a dropout rate of 10%,a total of 220 subjects were required,with 110 subjects in each group.\n\n1. experimental group The patients were given intravenous injection of 0.25 mg \u002F kg esketamine, 1.5 mg \u002F kg propofol and 1 mg \u002F kg succinylcholine in turn. After anesthesia, the patients were given electroconvulsive therapy.\n2. In the control group The patients were given normal saline consistent with esketamine injection volume, 1.5mg\u002Fkg of propofol and 1mg \u002F kg of succinylcholine. After anesthesia, the patients were given electroconvulsive therapy.\n\nEfficacy evaluation 1. Main efficacy indicators Response rate of depressive symptoms after MECT treatment Response is defined as two consecutive HAMD-24 scores ≤ 50% before treatment after receiving MECT treatment. The response rate is calculated as the number of patients who achieved as response divided by the total number of patients receiving MECT.In this study, the 24-item version of HAMD was utilized.\n\nParticipants will:\n\nBe randomly assigned to the esketamine group or the control group, and receive standard MECT treatment.\n\nHave seizure parameters, seizure duration, vital signs, and complications recorded.\n\nComplete psychiatric scale assessments, including HAMD-24, BSS, PANSS, WMS-RC and MoCA.\n\nBe assessed at the following time points: HAMD-24 and BSS after each treatment; PANSS after each treatment course;WMS-RC and MoCA before MECT and after one treatment course.\n\nAll subjects did not discontinue antidepressants before modified electroconvulsive therapy(MECT),and they were fasting for 8 hours and no fluids for 2 hours.Three minutes before MECT,continuous qCON monitoring(Apollo-9000A,Chongqing Xideer Medical Equipment Co.,Ltd.,China)was initiated,while monitoring blood pressure,heart rate,and peripheral capillary oxygen saturation.Preoxygenation was administered for 3 minutes.The qCON monitor uses three electrodes on the forehead to collect raw electroencephalogram(EEG)signals.The qCON monitoring includes the qCON index,qNOX index,burst suppression(BS),and signal quality index(SQI).",[52,53,54,55],"Esketamine","ECT","Depression","Adolescent","2026-01-06",{"date":58,"type":27},"2026-01-07",{"date":60,"type":27},"2025-11-25",{"date":62,"type":18},"2026-12-20",{"name":33,"class":34},2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":15,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":47,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":35},"100575846","quantitative-consciousness-index-monitoring-qnox-of-sedation-during-endoscopy-100575846","NCT06777589","Quantitative Consciousness Index Monitoring (qNOX) of Sedation During Endoscopy","Exploration of the Range of the Quantitative Nociception Index (qNOX) During Gastrointestinal Endoscopy Under Intravenous Sedation: a Multicenter Clinical Study","Inclusion Criteria\n\n1. Age between 18 and 60 years old;\n2. ASA-PS (American Society of Anesthesiologists Physical Status) classification of I to II;\n3. Body Mass Index (BMI): 18 to 28 kg\u002Fm²;\n4. Patients undergoing diagnostic and therapeutic procedures under sedation for lower gastrointestinal endoscopy;\n5. Clear understanding and voluntary participation in this study, with informed consent signed.\n\nExclusion Criteria\n\n1. Patients requiring complex endoscopic techniques for diagnosis and treatment;\n2. Patients who have participated in other clinical trials in the past three months;\n3. Pregnant and lactating patients;\n4. Patients with allergies to sedatives\u002Fanesthetics and other severe anesthesia risks;\n5. Patients with preoperative chronic pain or a history of substance abuse;\n6. Patients with severe neurological diseases such as stroke, hemiplegia, convulsions, epilepsy, etc.;\n7. Patients with known difficult airways such as limited mouth opening, restricted neck and jaw movement, rheumatoid spondylitis, temporomandibular joint arthritis, etc.;\n8. Patients with potentially life-threatening circulatory and respiratory diseases that are not adequately controlled, such as uncontrolled severe hypertension, severe arrhythmias, unstable angina pectoris, acute respiratory infections, asthma exacerbations, etc.;\n9. Patients with liver dysfunction (Child-Pugh Class C or higher), acute upper gastrointestinal bleeding with shock, severe anemia, gastrointestinal obstruction with gastric retention.",true,"18 Years","60 Years",{"count":76,"type":18},900,[78],"NA","Nociception is the encoding and processing of noxious stimulation and is considered an objective indicator for monitoring pain. Currently, a new clinically-applied medical-engineering integrated monitoring device for noxious stimulation response has emerged. Its fundamental principle is based on the monitoring of electroencephalographic (EEG) activity, incorporating two monitoring parameters: the quantitative consciousness (qCON) index and the quantitative nociceptive (qNOX) index. This device enables more precise monitoring of anesthesia depth, quantification of patients' anesthesia analgesia and stress levels, and reliable monitoring of responses to noxious stimulation. During tracheal intubation for general anesthesia, when the qCON value falls within the range of 40 to 60 and the qNOX value is between 30 and 50, it indicates that the patient is in an appropriate state of sedation and analgesia. However, there is currently no universally acknowledged standard for the optimal qNOX reference range during conscious sedation endoscopy. Therefore, this study utilizes the noxious stimulation response index (qNOX) to monitor noxious stimulation during the procedure, aiming to identify the best timing for inserting the endoscope during conscious sedation endoscopy and explore the appropriate range of qNOX for this purpose.",[81],"Nociception",[81,83,84],"endoscopy","Depth of anesthesia","2025-05-28",{"date":87,"type":27},"2025-06-02",{"date":89,"type":18},"2025-06-01",{"date":91,"type":18},"2025-08-31",{"name":33,"class":34},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":15,"minAge":73,"maxAge":74,"enrollmentInfo":100,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":35},"100562514","anesthesia-induction-scheme-for-painless-gastrointestinal-endoscopy-patients-based-on-nociceptive-stimulation-monitoring-100562514","NCT06604156","Anesthesia Induction Scheme for Painless Gastrointestinal Endoscopy Patients Based on Nociceptive Stimulation Monitoring","The Effect of the Nociception Index (qNOX) in Painless Gastrointestinal Endoscopy :a Clinical Study","Inclusion Criteria:\n\n1. Aged 18-60 years old;\n2. American Society of Anesthesiologists (ASA) Class I-III;\n3. Body mass index (BMI): 18-30 kg\u002Fm\\^2;\n4. Individuals scheduled for elective gastroscopy and colonoscopy examinations;\n5. Willing to comply with the experimental procedures and voluntarily sign the informed consent form\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding women;\n2. Individuals with allergies to sedatives\u002Fanesthetic drugs or other severe anesthetic risks;\n3. Patients with chronic preoperative pain or a history of substance abuse;\n4. Individuals with severe neurological diseases, such as stroke, hemiplegia, seizures, epilepsy, etc.;\n5. Patients with clearly difficult airways, such as those with limited mouth opening, neck or jaw mobility restrictions, rheumatoid arthritis, or temporomandibular joint disorders;\n6. Individuals with respiratory diseases, such as bronchitis, asthma, chronic obstructive pulmonary disease, or acute respiratory infections, which may lead to increased airway sensitivity;\n7. Patients with chronic pharyngitis, laryngitis, laryngeal edema, or recurrent laryngeal nerve paralysis that may affect normal throat function;\n8. Individuals with esophagitis, esophageal strictures, or esophageal motility disorders that may cause difficulty swallowing or reflux;\n9. Patients with poorly controlled life-threatening cardiovascular diseases, such as uncontrolled severe hypertension, severe arrhythmias, or unstable angina; 10.10.Patients with liver dysfunction (Child-Pugh grade C or above), acute upper gastrointestinal bleeding with shock, severe anemia, or gastrointestinal obstruction with retained gastric contents.",{"count":46,"type":18},"Nociception is the encoding and processing of noxious stimulation and is considered an objective indicator for monitoring pain. Currently, a new clinically-applied medical-engineering integrated monitoring device for noxious stimulation response has emerged. Its fundamental principle is based on the monitoring of electroencephalographic (EEG) activity, incorporating two monitoring parameters: the quantitative consciousness (qCON) index and the quantitative nociceptive (qNOX) index. However, in the context of sedation for gastrointestinal endoscopy, how the dynamic changes of the quantitative consciousness index (qCON) and the quantitative nociception index (qNOX) reflect the depth of sedation and nociceptive response remains unclear. Safe and effective sedation monitoring includes both direct visual monitoring and physiological monitoring, that is, monitoring the patient's hemodynamics and depth of sedation. This study utilizes qCON and qNOX monitoring to assess the sedation and analgesic states of patients undergoing painless gastroenterological endoscopy. By combining visual assessment (cough reflex, respiratory depression, and limb movement) with clinical physiological monitoring (vital signs monitoring and pulse oximetry), the aim is to explore the optimal sedation range for gastrointestinal endoscopy under sedation, providing new anesthesia monitoring tools for clinical use.",[103,81,104],"Depth of Anesthesia","Painless Gastrointestinal Endoscopy",[106,107,108],"Painless Gastrointestinal endoscopy","depth of anesthesia","nociception","2025-03-04",{"date":111,"type":27},"2025-03-06",{"date":113,"type":27},"2024-09-01",{"date":115,"type":18},"2025-10-31",{"name":33,"class":34},""]